KRAS and triple-negative breast carcinoma: Patients with advanced solid cancers (colorectal cancer, triple-negative breast cancer, pancreatic cancer, malignant melanoma, non-small cell lung cancer, and other cancers harboring KRAS, BRAF and NRAS mutation)